Cogent Biosciences
COGT
27 hedge funds and large institutions have $6.99M invested in Cogent Biosciences in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 12 closing their positions.
2.17% less ownership
Funds ownership: 10.09% → 7.92% (-2.2%)
25% less funds holding
Funds holding: 36 → 27 (-9)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
61% less capital invested
Capital invested by funds: $17.8M → $6.99M (-$10.8M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$348K |
| 2 |
CA
CHI Advisors
New York
|
+$153K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$138K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$77.3K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.05M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$682K |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$366K |
| 5 |
BlackRock
New York
|
-$150K |
COGT Hedge Fund Activity: Q4 2019 in Review
27 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2019, worth a combined $6.99M — down 61% from $17.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of COGT and 3 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $348K. The largest seller was Sectoral Asset Management, cutting an estimated $1.4M.
- 27 institutional investors held Cogent Biosciences (COGT) as of Q4 2019, down from 36 in Q3 2019.
- Funds reported $6.99M of Cogent Biosciences stock for Q4 2019, down 61% quarter-over-quarter.
- 3 funds opened new Cogent Biosciences positions in Q4 2019 and 12 closed out, a net change of -9 holders.
- The largest Cogent Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $348K added.
- The largest Cogent Biosciences seller in Q4 2019 was Sectoral Asset Management, an estimated $1.4M sold.
Based on aggregated 13F filings for Q4 2019.